This is not a game for the meek as targeted companies tend to come after such analysts with a vengeance. In one particularly heated litigation, Hemispherx Biopharma responded to claims that its highly touted drug Ampligen was worthless – causing the company’s stock price to plummet and enriching the short selling counter-analyst Manuel Asensio – by suing Asensio for defamation, seeking the $80 million in the drop in trial has been ordered. Since 1998, Asensio has attacked 28 companies for advancing poor drugs based on poor studies and some of the companies have been forced into bankruptcy or delisted from the stock exchanges following his charges. He has claimed his annual earnings are roughly $6 million per year. L. Stuart Ditzen. Philadelphia Inquirer Magazine July 14, 2002
“Can You Believe Econometric Evaluations of Law, Policy and Medicine?”